AcquisitionsJul 29, 2026, 04:03 PM
MIMEDX to Acquire Sanara MedTech for $350M
AI Summary
MIMEDX Group, Inc. announced a definitive merger agreement to acquire Sanara MedTech Inc. in a cash and stock transaction valued at approximately $350 million, or $35 per Sanara share. The acquisition aims to expand MIMEDX's surgical footprint, nearly doubling its surgical revenue, and is expected to be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin. The combined entity anticipates over $20 million in run-rate cost synergies and expects 2027 total revenue to exceed $400 million with an Adjusted EBITDA margin over 20%. The company also announced its second quarter 2026 operating and financial results alongside this transaction.
Key Highlights
- MIMEDX to acquire Sanara MedTech for approximately $350 million total enterprise value.
- Sanara shareholders to receive $33.00 cash and 0.4735 shares of MIMEDX common stock per share.
- Merger consideration represents a 46% premium to Sanara's 30-day volume weighted average share price.
- Transaction expected to be immediately accretive to revenue growth, gross margin, and Adjusted EBITDA margin.
- Anticipates over $20 million in run-rate cost synergies.
- Combined 2027 total revenue expected to exceed $400 million with over 20% Adjusted EBITDA margin.
- Cash portion financed through cash on hand and a new $300 million term loan.
- Transaction expected to close by year-end 2026, subject to shareholder and regulatory approvals.
Price Impact
More from MDXG